Obefazimod is an investigational small-molecule drug candidate developed for ulcerative colitis. It has been described as a first-in-class approach centered on microRNA-124 modulation. The compound remains in development rather than approved commercial use.
Abivax announced novel preclinical and clinical data for obefazimod at ECCO 2026, highlighting anti-fibrotic potential in Crohn's disease, favorable safety profile, and rapid onset of symptomatic relief in inflammatory bowel disease patients.
Drug Hunter's monthly molecule selections from July through December 2025 feature innovative small molecule candidates targeting pain, epilepsy, cancer, infectious diseases, and metabolic disorders, including non-opioid pain agents and precision therapies for rare conditions.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06456593 |
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease |
RECRUITING | PHASE2 |
